TICKERNERD
Menu
VERAVERAHealthcare · Biotechnology

VERA Stock Forecast: Vera Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$29
−6.89% on the day

The 15 Wall Street analysts covering Vera Therapeutics, Inc. hold a median 12-month price target of $80 — +175.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 21 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.2B
Ticker Nerd rank
27/ 100
Median analyst target
$80
Analysts covering
15
Revenue$0.0
Operating income−$112.5M
Net income−$109.5M
Free cash flow−$100.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.7%
1M
−19.9%
YTD
−42.6%
1Y
−3.0%
From 52W high
−47.8%
From 52W low
+20.5%
$24
$56
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VERA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
27/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
59
Accruals
56
Value
53
Issuance
45
Volatility
42
Revisions
35
Size
34
Quality
33
Growth
23

Momentum (59): The shares have been drifting up relative to others.

Growth (23): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VERA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VERA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26VERAHigh $100Median $80Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
13 Buy2 Hold0 Sell
Low $34Median $80High $100

The green dot is the last close — the median target sits +175.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
12 Oct 2026Leerink PartnersInitiatesMarket Perform$34
8 Sept 2026JP MorganMaintainsOverweight$76 → $83
8 Sept 2026JP MorganMaintainsOverweight—
17 Aug 2026WedbushReiteratesNeutral$34
17 Aug 2026WedbushReiteratesNeutral—
12 Aug 2026HC Wainwright & Co.MaintainsBuy$125 → $90
12 Aug 2026HC Wainwright & Co.MaintainsBuy—
11 Aug 2026WedbushMaintainsNeutral$43 → $34
11 Aug 2026WedbushMaintainsNeutral—
8 July 2026GuggenheimMaintainsBuy$56 → $76
8 July 2026GuggenheimMaintainsBuy—
8 July 2026HC Wainwright & Co.MaintainsBuy—
8 July 2026HC Wainwright & Co.MaintainsBuy$110 → $125
8 July 2026TD CowenMaintainsBuy$73 → $78
8 July 2026TD CowenMaintainsBuy—
8 July 2026WedbushMaintainsNeutral—
8 July 2026WedbushMaintainsNeutral$35 → $43
7 July 2026B of A SecuritiesMaintainsBuy$65 → $70
7 July 2026B of A SecuritiesMaintainsBuy—
15 May 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

VERA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

VERA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Vera Therapeutics, Inc. returned −3.0% against +15.6% for the S&P 500, dividends included.

VERA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26VERAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VERA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Vera Therapeutics, Inc. (VERA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.3×

Cheaper than 91% of US stocks

Price / sales
—
Price / book
5.3×

Cheaper than 18% of US stocks

EV / EBITDA
−4.4×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−91.8%

Higher than 14% of US stocks

Return on assets
−46.8%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vera Therapeutics, Inc. (VERA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vera Therapeutics, Inc. has a market value of $2.2B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$401.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$339.2M.

  • Shares outstanding: 72.0M.

  • Trailing P/E: −6.3×; forward P/E: −7.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Vera Therapeutics, Inc. employs 361 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

VERA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VERAVera Therapeutics, Inc.$2.2B27
RXRXRecursion Pharmaceuticals, Inc.$2.2B51
AGIOAgios Pharmaceuticals, Inc.$2.2B80
HRMYHarmony Biosciences Holdings, Inc.$2.2B84
AUPHAurinia Pharmaceuticals, Inc.$2.2B97
PHVSPharvaris NV$2.1B39
IMNMImmunome, Inc.$2.1B32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VERA news & analysis

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results

MarketBeat · 23 Oct 2026positive

Vera Therapeutics reported final efficacy results from the Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The data were presented at the American Society of Nephrology’s Kidney Week meeting and published in The New England Journal of Medicine.

Why it matters — The report highlights clinical trial data for Vera’s atacicept program in IgA nephropathy.

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine

GlobeNewsWire · 22 Oct 2026positive

Vera Therapeutics reported that the final ORIGIN 3 efficacy analysis of TRUTAKNA in IgA nephropathy met all prespecified endpoints, including measures of eGFR change and kidney disease progression risk. The results were presented at ASN Kidney Week 2026 and published in the New England Journal of Medicine; the excerpt also described a favorable safety profile generally comparable to placebo.

Why it matters — The reported efficacy and safety findings are relevant to VERA watchers tracking evidence for TRUTAKNA in IgA nephropathy.

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

GlobeNewsWire · 20 Oct 2026neutral

Vera Therapeutics announced an investor webcast at 4:30 p.m. ET on October 22 to discuss the final efficacy results from the ORIGIN 3 study of TRUTAKNA (atacicept-vymj), featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026. Its third-quarter 2026 financial results webcast is also scheduled for 4:30 p.m.

Why it matters — Investors can hear the ORIGIN 3 results and the company’s third-quarter 2026 financial update through the scheduled webcast.

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

Vera Therapeutics announced that its Compensation Committee granted inducement awards on September 29, 2026, consisting of non-qualified stock options for 16,700 shares and restricted stock units for 8,350 shares of Class A common stock to five new employees under the company's Inducement Plan.

Why it matters — This disclosure reports standard equity compensation for newly hired employees under Nasdaq listing rules and reflects routine hiring activity rather than any operational or financial change for the company.

FAQ

Frequently asked questions about VERA stock

What is the VERA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Vera Therapeutics, Inc. have a median 12-month price target of $80, with estimates ranging from $34 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VERA stock a buy right now?

Of the 15 analysts covering Vera Therapeutics, Inc., 13 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vera Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VERA?

As at 21 Oct 2026, Vera Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (59 of 100).

Will VERA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +175.4% from the last close, and Ticker Nerd's factor model ranks Vera Therapeutics, Inc. 27 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VERA stock forecast for 2030?

No analyst covering Vera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VERA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $100 over the next 12 months.

How has VERA stock performed over the past year?

Vera Therapeutics, Inc. returned -3.0% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vera Therapeutics, Inc. do?

Vera Therapeutics, Inc. Class A Common Stock represents ownership in Vera Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases.

What is the latest news on VERA?

The most recent item we track (MarketBeat, 23 Oct 2026): "Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results". Vera Therapeutics reported final efficacy results from the Phase III ORIGIN trial evaluating atacicept, marketed as TRUTAKNA, in adults with IgA nephropathy. The data were presented at the American Society of Nephrology’s Kidney Week meeting and published in The New England Journal of Medicine.

Company

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc. Class A Common Stock represents ownership in Vera Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases. The company’s current pipeline is centered on atacicept, a subcutaneous therapy being evaluated for IgA nephropathy and other autoimmune kidney diseases, alongside additional programs such as MAU868 for BK viremia infections and VT-109 for B cell-mediated autoimmune diseases. Vera Therapeutics operates in the biotechnology and health technology sectors, where its work targets conditions driven by abnormal immune activity and unmet medical needs. Headquartered in Brisbane, California, the company’s business today is centered on advancing immunology-focused drug candidates through clinical development and toward commercialization.

CEO Dr. Marshall W. Fordyce M.D. · 361 employees · United States · https://veratx.com